Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. develops and commercializes graphene-enabled and advanced material technologies through platforms that include ZenGUARD™, Albany Graphite and Triera. Company developments center on ZenGUARD™ enhanced air filters and related regulatory classification, commercialization pathways and HVAC supply-chain opportunities.
Recurring updates also cover the Albany Graphite Project in Ontario, including technical studies, environmental and social baseline work, market analysis and high-purity graphite positioning for nuclear, defence, battery and industrial markets. Triera Biosciences updates focus on aptamer discovery, biosensor enablement, machine-learning classification and infectious-disease applications, alongside material agreements, capital-structure disclosure, governance matters and operating results.
Zentek Ltd. (Nasdaq:ZTEK), an intellectual property development company, announced the results of Phase 2 testing for its ZenGUARD™ technology in HVAC filtration. The ZenGUARD™ treated MERV 8 filters achieved a 34.56% filtration efficiency against the Phi6 virus, significantly improving from 7.24% in untreated filters. This advancement positions ZenGUARD™ as a potential game-changer for enhancing indoor air quality without incurring high costs for filter upgrades. Zentek is progressing towards commercialization, collaborating with federal organizations and seeking regulatory approvals in North America.
Zentek Ltd. (NASDAQ:ZTEK) has entered a Distribution Agreement with Southmedic Inc. for the distribution of its patented ZenGUARD™ surgical masks in Canada. Southmedic, a leading medical device distributor, aims to introduce ZenGUARD™ masks to hospitals, clinics, and long-term care facilities. This partnership is expected to secure stable demand in the surgical mask market, leveraging Southmedic's established network. Zentek’s ZenGUARD™ technology boasts 99% antimicrobial activity and enhanced filtration efficiency, reinforcing its value proposition in healthcare.
Zentek Ltd. (Nasdaq:ZTEK) announced the appointment of Mitch Swergold as the new Director of Investor Relations. Swergold brings extensive experience in technology investment as a former Senior Analyst and Portfolio Manager. His role will involve enhancing communication with investors and presenting updated business information. Concurrently, Zentek granted him 50,000 stock options at an exercise price of $1.93. The company's innovative products, particularly the antimicrobial ZenGUARD coating, continue to drive its mission in the healthcare sector.
Zentek Ltd. (NASDAQ:ZTEK) announced successful results from Phase 2 HVAC filter testing conducted by the National Research Council of Canada. The ZenGUARD™ coating applied to standard HVAC filters significantly reduced airborne contaminants without affecting airflow rates or energy consumption. This breakthrough could enhance air quality across various sectors, from healthcare to real estate. Zentek plans to further optimize filter configurations and finalize regulatory submissions, moving closer to commercializing ZenGUARD™ products.
Zentek Ltd. (NASDAQ:ZTEK) has been granted Patent Number 3,152,759 by the Canadian Intellectual Property Office for its ZenGUARD™ technology, which includes graphene-silver composites with antimicrobial uses. This patent, valid until September 20, 2041, supports applications in personal protective equipment (PPE) and HVAC systems. CEO Greg Fenton noted the significance of moving from concept to commercialization, emphasizing the importance of intellectual property and the technology's potential to enhance safety and environmental protection.
Zentek Ltd. (NASDAQ:ZTEK) has filed amended and restated audited financial statements for the year ending March 31, 2022. This update reflects necessary amendments requested by the Ontario Securities Commission due to changes in auditors. The amended financials now include the predecessor auditor's report for the comparative period. Zentek operates in the development of graphene and nanomaterials for healthcare, with its ZenGUARD™ coating demonstrating 99% antimicrobial activity, including against COVID-19.
Zentek Ltd. (NASDAQ:ZTEK) has announced a 4-year, $1.6M research project with the University of Toronto and Ford's Powertrain Engineering Research Development Centre to develop next-generation graphene-based battery materials. Funded in part by $1.2M from the Mitacs Accelerate program, the project aims to enhance energy density and charging rates for automotive batteries. Notably, Zentek has developed a patent-pending graphene-wrapped silicon anode material that demonstrates significant improvements in capacity and cycle stability, potentially revolutionizing electric vehicle battery technology.
Zentek Ltd. (NASDAQ:ZTEK) has been selected to present its ZenGUARD™ technology at the 12th Annual Global Summit on Regulatory Science in October 2022. The summit focuses on nanotechnology advancements in medical products, and Zentek will showcase its patent-pending antimicrobial coating, proven to have 99% efficacy against various pathogens. Notable speakers from global regulatory bodies, including the FDA and Health Canada, will also participate. Additionally, the company has granted options for 150,000 common shares at $1.93 to certain officers and employees.
Zentek Ltd. (Nasdaq: ZTEK) announced the results from its annual and special meeting held on September 29, 2022. Shareholders approved all resolutions, including the election of the board of directors, with high approval rates: Francis Dube (95.689%), Greg Fenton (98.98%), and Eric Wallman (99.530%). Other approved items include appointing BDO Canada LLP as auditors (98.871%) and adopting a long-term incentive plan (91.766%). Dr. Francis Dube expressed satisfaction with the strong support from shareholders as the company focuses on advancing nanotechnologies.
Zentek Ltd. (NASDAQ:ZTEK) announced that its Canadian patent application for its ZenGUARD™ technology, utilized in personal protective equipment (PPE) and HVAC systems, has been allowed by the Canadian Intellectual Property Office. All 54 claims in the application were granted, marking a significant milestone in Zentek's strategy for global patent protection. CEO Greg Fenton emphasized the importance of this achievement in validating the company's IP development model. ZenGUARD™ has demonstrated 99% antimicrobial activity, including against COVID-19, enhancing its commercial potential.